×

Argos Therapeutics to Present at 21st Annual Future Leaders in the Biotech Industry Conference

DURHAM, N.C., March 21, 2014 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), a biopharmaceutical company focused on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced that Jeffrey Abbey, president and chief executive officer, will present at the upcoming 21st Annual Future Leaders in the Biotech Industry conference. Mr. Abbey will provide a review of progress in the pivotal ADAPT Phase 3 clinical trial for AGS-003, Argos's fully personalized immunotherapy currently in development for the treatment of metastatic renal cell carcinoma, and additional updates for the AGS-004 Phase 2 program in HIV. The conference will be held at the Millennium Broadway Hotel & Conference Center in New York City.

Event: 21st Annual Future Leaders in the Biotech Industry Conference
Date: Friday, March 28, 2014
Time: 10:30 a.m ET

A live audio webcast of the presentation can be accessed via the Investors section of the Company's website at www.argostherapeutics.com. Please log in approximately 5-10 minutes before the event to ensure a timely connection. A replay of the webcast will be available for 14 days following the presentation.

About Argos Therapeutics

Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform. Argos´ most advanced product candidate, AGS-003, is being evaluated in the pivotal ADAPT Phase 3 clinical trial for the treatment of metastatic renal carcinoma (mRCC). The company also plans to report data from its Phase 2b trial of AGS-004 for the treatment of HIV in mid-2014. For more information about Argos Therapeutics, visit www.argostherapeutics.com.

CONTACT: Media: Andrea Coan Berry & Company Public Relations acoan@berrypr.com (212) 253-8881 Investors: Angeli Kolhatkar Burns McClellan akolhatkar@burnsmc.com (212) 213-0006Source:Argos Therapeutics, Inc.